Myriad Genetics Publishes Validation of FirstGene Prenatal Screening
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy MYGN?
Source: Newsfilter
- Validation Results: Myriad Genetics' publication on the FirstGene Multiple Prenatal Screen shows that every test component achieved ≥98.2% analytical sensitivity and ≥99.0% analytical specificity, indicating exceptional accuracy and reliability in prenatal screening, which enhances clinicians' confidence in the results.
- Clinical Application Outlook: The test evaluated nearly 500 samples, covering fetal aneuploidy, RhD compatibility, and 19 severe recessive conditions, aiming to streamline prenatal genetic risk assessment by integrating multiple testing modalities, thereby improving screening rates among pregnant women in the U.S. and enhancing clinical practices.
- Technological Innovation: The FirstGene screen employs fetal-fraction amplification and a novel trajectory analysis algorithm to enhance genotype resolution, which not only improves test accuracy but also marks a significant milestone towards broad commercialization of prenatal screening technologies by Myriad.
- CONNECTOR Study Launch: The FirstGene screen is currently utilized in the CONNECTOR study, designed to evaluate test performance in real-world clinical settings, generating evidence to support clinical validity and utility as FirstGene advances towards full commercial launch.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MYGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MYGN
Wall Street analysts forecast MYGN stock price to rise
5 Analyst Rating
2 Buy
2 Hold
1 Sell
Hold
Current: 4.290
Low
4.00
Averages
7.38
High
9.00
Current: 4.290
Low
4.00
Averages
7.38
High
9.00
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Myriad Genetics (MYGN) Q4 2025 Earnings Transcript
See More
Myriad Genetics Q4 Earnings Exceed Expectations
- Earnings Beat: Myriad Genetics reported a Q4 non-GAAP EPS of $0.04, exceeding expectations by $0.06, indicating robust profitability that boosts investor confidence in the company's financial health.
- Slight Revenue Decline: The Q4 revenue stood at $209.8 million, a 0.4% year-over-year decrease, yet it surpassed expectations by $2.24 million, demonstrating the company's ability to maintain revenue stability in a competitive landscape.
- Volume Growth Drivers: Key drivers of year-over-year test volume growth in Q4 included a 12% increase in Prolaris prostate cancer testing, a 9% rise in hereditary cancer testing, and a 9% growth in GeneSight, reflecting ongoing innovation and demand in precision medicine.
- Stable Gross Margin: The gross margin for Q4 was 70.0%, consistent with Q3, showcasing effective cost management and operational efficiency that support long-term profitability prospects.
See More
Myriad Genetics to Announce Q4 Earnings on February 23
- Earnings Announcement Date: Myriad Genetics (MYGN) is set to announce its Q4 fiscal year 2023 earnings on February 23 after market close, with a consensus EPS estimate of -$0.02, reflecting a significant year-over-year decline of 166.7%, indicating pressure on profitability.
- Revenue Expectations Decline: The revenue estimate for the quarter stands at $207.56 million, down 1.4% year-over-year, highlighting challenges the company faces amid intensified market competition and demand fluctuations, which may impact investor confidence moving forward.
- Historical Performance Metrics: Over the past two years, MYGN has exceeded EPS and revenue estimates 88% of the time, although recent trends show no upward revisions in EPS estimates and three downward revisions, suggesting a cautious outlook from analysts regarding the company's future performance.
- Revision Trend Analysis: While there have been two upward revisions in revenue estimates, there have also been three downward revisions, indicating a conservative market sentiment towards Myriad Genetics' growth prospects, which could affect its stock price performance.
See More
Myriad Genetics Publishes Validation of FirstGene Prenatal Screening
- Validation Results: Myriad Genetics' publication on the FirstGene Multiple Prenatal Screen shows that every test component achieved ≥98.2% analytical sensitivity and ≥99.0% analytical specificity, indicating exceptional accuracy and reliability in prenatal screening, which enhances clinicians' confidence in the results.
- Clinical Application Outlook: The test evaluated nearly 500 samples, covering fetal aneuploidy, RhD compatibility, and 19 severe recessive conditions, aiming to streamline prenatal genetic risk assessment by integrating multiple testing modalities, thereby improving screening rates among pregnant women in the U.S. and enhancing clinical practices.
- Technological Innovation: The FirstGene screen employs fetal-fraction amplification and a novel trajectory analysis algorithm to enhance genotype resolution, which not only improves test accuracy but also marks a significant milestone towards broad commercialization of prenatal screening technologies by Myriad.
- CONNECTOR Study Launch: The FirstGene screen is currently utilized in the CONNECTOR study, designed to evaluate test performance in real-world clinical settings, generating evidence to support clinical validity and utility as FirstGene advances towards full commercial launch.
See More
Myriad Genetics Schedules Q4 and Full Year 2025 Earnings Call
- Earnings Call Scheduled: Myriad Genetics will hold its Q4 and full year 2025 earnings conference call on February 23, 2026, at 4:30 PM ET, releasing its quarterly earnings the same day, which is expected to impact investor confidence positively.
- Investor Conference Participation: Executives Sam Raha and Ben Wheeler will participate in several investor healthcare conferences, including the TD Cowen Annual Healthcare Conference on March 3 and the Leerink Partners Global Healthcare Conference on March 10, aimed at enhancing the company's visibility and credibility among investors.
- Webcast Accessibility: Investors can access live and archived webcasts of the earnings call on Myriad's Investor Relations website, which enhances transparency and provides convenient information access, likely attracting more potential investors.
- Leadership in Genetic Testing: Myriad Genetics focuses on genetic testing and precision medicine, aiming to improve patient care quality and reduce healthcare costs through disease risk assessment and treatment guidance, further solidifying its leadership position in the industry.
See More
Myriad Genetics Unveils Commercialization Roadmap for Precise MRD Assay
- Technological Innovation: Myriad Genetics' Precise MRD assay utilizes ultrasensitive circulating tumor DNA detection to provide critical clinical insights across various cancer types, marking a significant breakthrough in molecular diagnostics.
- Market Launch Plan: The company plans a limited launch of Precise MRD with select community-based clinicians in breast cancer starting March 2026, followed by expansions into colorectal and renal cancers later that year, indicating a phased market entry strategy.
- Clinical Research Findings: Interim clinical studies demonstrate the assay's ability to detect ctDNA down to one part per million, with high baseline sensitivity and strong predictive power for recurrence and treatment response in breast and colorectal cancers, further validating its potential role in precision oncology.
- Academic Recognition: These findings have been presented at leading medical conferences and published in peer-reviewed journals, enhancing the credibility and market acceptance of Precise MRD in real-world applications.
See More
Myriad Genetics (MYGN) Q4 2025 Earnings Transcript
See More
Myriad Genetics Q4 Earnings Exceed Expectations
- Earnings Beat: Myriad Genetics reported a Q4 non-GAAP EPS of $0.04, exceeding expectations by $0.06, indicating robust profitability that boosts investor confidence in the company's financial health.
- Slight Revenue Decline: The Q4 revenue stood at $209.8 million, a 0.4% year-over-year decrease, yet it surpassed expectations by $2.24 million, demonstrating the company's ability to maintain revenue stability in a competitive landscape.
- Volume Growth Drivers: Key drivers of year-over-year test volume growth in Q4 included a 12% increase in Prolaris prostate cancer testing, a 9% rise in hereditary cancer testing, and a 9% growth in GeneSight, reflecting ongoing innovation and demand in precision medicine.
- Stable Gross Margin: The gross margin for Q4 was 70.0%, consistent with Q3, showcasing effective cost management and operational efficiency that support long-term profitability prospects.
See More
Myriad Genetics to Announce Q4 Earnings on February 23
- Earnings Announcement Date: Myriad Genetics (MYGN) is set to announce its Q4 fiscal year 2023 earnings on February 23 after market close, with a consensus EPS estimate of -$0.02, reflecting a significant year-over-year decline of 166.7%, indicating pressure on profitability.
- Revenue Expectations Decline: The revenue estimate for the quarter stands at $207.56 million, down 1.4% year-over-year, highlighting challenges the company faces amid intensified market competition and demand fluctuations, which may impact investor confidence moving forward.
- Historical Performance Metrics: Over the past two years, MYGN has exceeded EPS and revenue estimates 88% of the time, although recent trends show no upward revisions in EPS estimates and three downward revisions, suggesting a cautious outlook from analysts regarding the company's future performance.
- Revision Trend Analysis: While there have been two upward revisions in revenue estimates, there have also been three downward revisions, indicating a conservative market sentiment towards Myriad Genetics' growth prospects, which could affect its stock price performance.
See More
Myriad Genetics Publishes Validation of FirstGene Prenatal Screening
- Validation Results: Myriad Genetics' publication on the FirstGene Multiple Prenatal Screen shows that every test component achieved ≥98.2% analytical sensitivity and ≥99.0% analytical specificity, indicating exceptional accuracy and reliability in prenatal screening, which enhances clinicians' confidence in the results.
- Clinical Application Outlook: The test evaluated nearly 500 samples, covering fetal aneuploidy, RhD compatibility, and 19 severe recessive conditions, aiming to streamline prenatal genetic risk assessment by integrating multiple testing modalities, thereby improving screening rates among pregnant women in the U.S. and enhancing clinical practices.
- Technological Innovation: The FirstGene screen employs fetal-fraction amplification and a novel trajectory analysis algorithm to enhance genotype resolution, which not only improves test accuracy but also marks a significant milestone towards broad commercialization of prenatal screening technologies by Myriad.
- CONNECTOR Study Launch: The FirstGene screen is currently utilized in the CONNECTOR study, designed to evaluate test performance in real-world clinical settings, generating evidence to support clinical validity and utility as FirstGene advances towards full commercial launch.
See More
Myriad Genetics Schedules Q4 and Full Year 2025 Earnings Call
- Earnings Call Scheduled: Myriad Genetics will hold its Q4 and full year 2025 earnings conference call on February 23, 2026, at 4:30 PM ET, releasing its quarterly earnings the same day, which is expected to impact investor confidence positively.
- Investor Conference Participation: Executives Sam Raha and Ben Wheeler will participate in several investor healthcare conferences, including the TD Cowen Annual Healthcare Conference on March 3 and the Leerink Partners Global Healthcare Conference on March 10, aimed at enhancing the company's visibility and credibility among investors.
- Webcast Accessibility: Investors can access live and archived webcasts of the earnings call on Myriad's Investor Relations website, which enhances transparency and provides convenient information access, likely attracting more potential investors.
- Leadership in Genetic Testing: Myriad Genetics focuses on genetic testing and precision medicine, aiming to improve patient care quality and reduce healthcare costs through disease risk assessment and treatment guidance, further solidifying its leadership position in the industry.
See More
Myriad Genetics Unveils Commercialization Roadmap for Precise MRD Assay
- Technological Innovation: Myriad Genetics' Precise MRD assay utilizes ultrasensitive circulating tumor DNA detection to provide critical clinical insights across various cancer types, marking a significant breakthrough in molecular diagnostics.
- Market Launch Plan: The company plans a limited launch of Precise MRD with select community-based clinicians in breast cancer starting March 2026, followed by expansions into colorectal and renal cancers later that year, indicating a phased market entry strategy.
- Clinical Research Findings: Interim clinical studies demonstrate the assay's ability to detect ctDNA down to one part per million, with high baseline sensitivity and strong predictive power for recurrence and treatment response in breast and colorectal cancers, further validating its potential role in precision oncology.
- Academic Recognition: These findings have been presented at leading medical conferences and published in peer-reviewed journals, enhancing the credibility and market acceptance of Precise MRD in real-world applications.
See More
